share_log

Benchmark Maintains Buy on Biofrontera, Lowers Price Target to $18

Benzinga ·  Jul 5, 2023 07:50

Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $140 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment